A field review is reframing CAR-T manufacturing around an in vivo concept—moving the engineering steps into the patient rather than relying on centralized ex vivo production. The review details how this approach could eliminate manufacturing bottlenecks such as leukapheresis logistics, shipping delays, ex vivo expansion variability, contamination risk, and the window where aggressive cancers progress or patients deteriorate. Complementing that, new clinical and translational data are also being used to define success predictors in “off-the-shelf” CAR-T. An MD Anderson study reported that pre-existing immune rejection and donor CAR-T intrinsic fitness help determine which patients benefit from universal-style products. Together, the developments signal an industry shift from treating manufacturing merely as an operational constraint toward using immunobiology and process redesign to expand eligibility and improve outcomes. For biotech teams, the key takeaway is the convergence of manufacturing innovation with biomarkers that predict cell therapy response and persistence.